iCARE4CVD Individualised Care from Early Risk of Cardiovascular Disease to Established Heart Failure
- Coordinator
- Universiteit Maastricht, Netherlands
- Runs
- 1 October 2023 to 31 March 2028
- Status
- Running
- EU funding
- €9.9m
- Total cost
- €21.5m
- Partners
- 47 organisations in 15 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101112022
What the project is doing
In the project's own words, from its summary on CORDIS.
The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5 year mortality rate of 20-50% despite significant advances in therapy.iCARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup.
This will be achieved by the following steps: clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood, imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-based modeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responses to therapy.
Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Results will be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative future trials to individualise prevention and therapy.
Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board, country-specific Patient Panels) to build a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resources and expertise from the public and private side to bring iCARE4CVD to success.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Maastricht | Maastricht | Netherlands | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| Amgen | Diegem | Belgium | Participant |
| Huawei Technologies Research & Development Belgium | Gent | Belgium | Associatedpartner |
| Thomas More Kempen Vzw | Geel | Belgium | Participant |
| Decentriq AG | Zurich | Switzerland | Participant |
| Eli Lilly Export SA | Vernier | Switzerland | Associatedpartner |
| Exploris Health AG | Wallisellen | Switzerland | Associatedpartner |
| F. Hoffmann-La Roche AG | Basel | Switzerland | Participant |
| Sib Swiss Institute of Bioinformatics | Genf | Switzerland | Associatedpartner |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Deutsche Stiftung Fur Chronisch Kranke | Furth | Germany | Participant |
| Evotec International GmbH | Hamburg | Germany | Participant |
| Lilly Deutschland GmbH | Bad Homburg | Germany | Associatedpartner |
| Universitaetsklinikum Aachen | Aachen | Germany | Participant |
| Wig2 GmbH | Leipzig | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Bayer Hispania SL | Sant Joan Despi | Spain | Third party |
| Huawei Technologies Oy (finland) Co Ltd | Helsinki | Finland | Participant |
| Precordior Oy | Turku | Finland | Participant |
| Bayer Healthcare SAS | Loos | France | Third party |
| Fondation Francophone Pour La Recherche Sur Le Diabete | Paris | France | Participant |
| Huawei Technologies France | Boulogne-Billancourt | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Capsicohealthcare Limited | Dublin | Ireland | Participant |
| University College Dublin, National University of Ireland, Dublin | Dublin | Ireland | Participant |
| Fondazione Human Technopole | Milano | Italy | Participant |
| Istituto Di Ricerche Farmacologiche Mario Negri | Milano | Italy | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Participant |
| Academisch Ziekenhuis Maastricht | Maastricht | Netherlands | Participant |
| Ancora Health BV | Groningen | Netherlands | Participant |
| Catalyze B.V. | Amsterdam-Duivendrecht | Netherlands | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek TNO | Den Haag | Netherlands | Participant |
| Philips Medical Systems Nederland BV | Best | Netherlands | Participant |
| Stichting IMEC Nederland | Eindhoven | Netherlands | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Participant |
| Orbital Global Group Limited | Stowmarket | United Kingdom | Associatedpartner |
| The Queen's University of Belfast | Belfast | United Kingdom | Associatedpartner |
| University of Glasgow | Glasgow | United Kingdom | Associatedpartner |
| University of Ulster | Coleraine | United Kingdom | Associatedpartner |
| Bayer Healthcare Llc | Whippany | United States | Third party |
| Breakthrough T1d | New York | United States | Participant |
| Eli Lilly and Company | Indianapolis | United States | Participant |
| University of Cape Town | Rondebosch | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI